Bicycle Therapeutics BCYC
NASDAQ BCYC
$4.28 +0.05 (+1.06%)
As of: Sep 4, 2026 · 12:41 PM EDT

Bicycle Therapeutics (BCYC) Non Operating Interest Expenses (2021 - 2026)

Analysis

Bicycle Therapeutics (BCYC) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Bicycle Therapeutics 299.11 Mn 299.11 Mn - 44,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 44,000.00
Mar 31, 2026 48,000.00
Dec 31, 2025 57,000.00
Sep 30, 2025 44,000.00
Jun 30, 2025 54,000.00
Mar 31, 2025 51,000.00
Dec 31, 2024 52,000.00
Sep 30, 2024 33,000.00
Jun 30, 2024 824,000.00
Mar 31, 2024 821,000.00
Dec 31, 2023 820,000.00
Sep 30, 2023 814,000.00
Jun 30, 2023 821,000.00
Mar 31, 2023 808,000.00
Dec 31, 2022 826,000.00
Sep 30, 2022 817,000.00
Jun 30, 2022 883,000.00
Mar 31, 2022 818,000.00
Dec 31, 2021 820,000.00
Sep 30, 2021 823,000.00